Bard PowerPort Lawsuit [September 2026 Update] - File A Claim

Attorneys are scheduled to meet for a final pretrial conference ahead of the third Bard PowerPort bellwether trial.

The trial involves a Florida plaintiff’s infection claims tied to a PowerPort implanted in August 2013.

Scheduled to begin on October 13th, this trial will be split into two phases, with jurors first deciding liability before considering punitive damages if Bard is found liable.

The case follows two earlier bellwether trials that concluded with very different outcomes.

The first ended in a defense verdict, though the plaintiff has since moved for a mistrial, arguing jurors received improper instructions and were pressured to reach a verdict before finishing deliberations.

The second trial, decided earlier this month, resulted in a $40 million award for a New Mexico woman whose catheter fragment allegedly traveled to her heart.

According to a proposed pretrial order filed September 9th, attorneys estimate the upcoming trial will require about 66 hours of courtroom time.

Two more bellwether trials are already scheduled for December 1st, 2026 and February 2nd, 2027.

Bard currently faces more than 3,700 PowerPort lawsuits consolidated in the District of Arizona.

A federal jury awarded $40 million in the second bellwether trial over Bard’s PowerPort device, delivered Friday in the U.S. District Court for the District of Arizona. 

The plaintiff sued Bard after requiring emergency surgery in 2019 to remove a seven-inch section of broken catheter that had become lodged in her heart. She had received the PowerPort implant two years earlier, in 2017. 

The verdict follows a very different outcome in the first bellwether trial in May, which ended in a split decision. 

This second trial focused on allegations that the catheter material degrades over time, leading to cracking, fracturing, and migration inside the body.

Three more bellwether trials are already scheduled, set for October 13, December 1, and February 2, 2027. 

With one defense-leaning split verdict and now one substantial plaintiff win on the books, attorneys on both sides are expected to weigh this result heavily as the litigation heads toward those next trials and any potential settlement talks.

The Bard PowerPort MDL recorded no change between August and September, holding steady at 3,734 cases.

The flat docket follows months of substantial growth and comes as the litigation moves forward following the first PowerPort bellwether trial, which ended in a defense verdict for Bard.

Expert testimony involving alleged catheter fractures, migration, and other device failures remains a key issue for future cases.

Despite the pause in new filings, more than 3,700 Bard PowerPort lawsuits remain pending in the federal MDL.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort lawsuit right now? 

You can use the chat feature on this page to find out if you qualify in just minutes.

The number of Bard PowerPort lawsuits has climbed to nearly 4,000 ahead of the MDL’s second bellwether trial. 

The trial is set to begin August 18 in the District of Arizona, centering a plaintiff from New Mexico whose port catheter fractured and migrated near her heart.

She required emergency surgery to remove the fragments. 

The first bellwether trial ended in May with a mixed verdict.

The outcome of this next bellwether trial could shape settlement talks across the broader MDL.

The Bard PowerPort MDL added 170 cases between July and August, increasing from 3,564 to 3,734.

The continued growth comes as the parties prepare for additional bellwether trials following the first defense verdict, while the court continues resolving disputes over expert testimony that will shape future cases involving catheter fractures, migration, and infections.

With more than 3,700 pending lawsuits, the Bard PowerPort MDL remains one of the fastest-growing medical device litigations in the federal court system.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chat feature on this page to find out if you qualify in just minutes.

The second bellwether trial in the Bard PowerPort MDL is scheduled to begin on August 18, 2026, in the U.S. District Court for the District of Arizona before Judge David G. Campbell.

Court filings submitted ahead of trial outline the evidence and legal issues expected to be presented as the parties prepare to argue whether Bard’s implantable port catheters were defectively designed and whether the company should be held liable for plaintiffs’ injuries.

One issue the court must resolve before trial is Bard’s request to divide the proceedings into two phases. Under the proposal, the jury would first decide whether Bard is liable before considering punitive damages in a separate phase.

Plaintiff Kimberly Divelbliss opposes the request, arguing much of the evidence supporting punitive damages also relates directly to Bard’s knowledge of the alleged defects and should be presented together.

The upcoming trial is the second of six bellwether cases selected from more than 3,500 lawsuits pending in the federal MDL.

Plaintiffs allege Bard PowerPort catheters are prone to cracking, fracturing, and material degradation, which can lead to catheter migration, blood clots, infections, pulmonary embolism, and other serious complications.

The first bellwether trial ended with a defense verdict on several claims and a hung jury on others. The plaintiff has since asked the court for a new trial, arguing the jury received incorrect legal instructions.

The second bellwether is expected to provide another indication of how juries evaluate the evidence and legal claims common to the PowerPort litigation.

The Bard PowerPort MDL added 188 cases between June and July, increasing from 3,376 to 3,564.

The continued growth comes as the litigation moves beyond the first bellwether trial, with both sides continuing to litigate expert witness qualifications that will shape future trials involving catheter fractures, migration, and other alleged device failures.

The court’s upcoming rulings on expert testimony are expected to play a significant role in the next phase of the Bard PowerPort litigation.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now?

You can use the chat feature on this page to find out if you qualify in just minutes.

A recent legal analysis examines how even highly qualified expert witnesses may face exclusion if courts determine their expertise is too narrowly focused for the opinions they offer at trial.

The article points to recent product liability decisions, including the Bard PowerPort MDL, where a federal judge excluded portions of a physician’s testimony after finding that extensive experience implanting and managing ports did not automatically qualify the expert to offer opinions on the cause of a patient’s bloodstream infection.

The authors note that courts are increasingly examining whether an expert’s education, publications, certifications, and professional experience directly match the specific opinions they intend to provide.

The issue is particularly relevant in complex medical device litigation, where expert testimony often plays a central role in proving defect, causation, and damages.

As Bard PowerPort lawsuits continue toward additional bellwether trials, disputes over the qualifications and scope of expert testimony are likely to remain an important part of pretrial proceedings.

The plaintiff in the first Bard PowerPort bellwether trial is asking the court to grant a new trial after arguing that jury instructions improperly influenced deliberations and contributed to the defense verdict.

Following the May trial, the Arizona jury found in favor of C.R. Bard and Becton Dickinson on failure-to-warn claims but could not reach a unanimous decision on whether the PowerPort catheter was defectively designed.

On June 3, the plaintiff filed a motion seeking a mistrial and judgment as a matter of law, arguing jurors were confused by instructions and mistakenly believed they faced a deadline to reach a decision.

According to the motion, jurors deliberated for about 11 hours before returning a partial verdict and repeatedly requested clarification on issues involving design defect, failure to warn, and superseding cause.

The plaintiff’s attorneys argue the court’s instructions suggested unanimity was unnecessary and improperly allowed a partial verdict before deliberations had fully run their course.

The motion is one of the first major post-trial developments in the Bard PowerPort lawsuit and could affect how future bellwether cases proceed.

The second Bard PowerPort bellwether trial remains scheduled to begin on August 18, with additional trials already set through early 2027 as more than 3,000 Bard PowerPort lawsuits continue through the MDL in Arizona.

A federal judge overseeing the Bard PowerPort multidistrict litigation has designated a catheter fracture case as the second bellwether trial, with proceedings scheduled to begin in August 2026.

The case will serve as an important test of claims alleging that Bard PowerPort catheters were defectively designed and prone to fracturing inside the body.

The trial follows the first bellwether case, which involved infection-related allegations and resulted in a partial defense verdict while jurors were unable to reach a unanimous decision on key design defect claims.

As a result, the upcoming fracture case is expected to place greater focus on allegations that the catheter material deteriorates over time, leading to cracks, fractures, migration, embolization, and other serious complications.

According to the litigation, plaintiffs allege Bard designed the PowerPort catheter using a polyurethane material containing barium sulfate that can create structural weaknesses and increase the likelihood of device failure.The August trial is particularly important because catheter fracture and migration claims are considered among the strongest injury allegations in the PowerPort litigation and may provide a clearer assessment of how juries respond to plaintiffs’ core design defect theories.

The Bard PowerPort MDL added 189 cases between May and June, increasing from 3,187 to 3,376.

The growth follows the first Bard PowerPort bellwether trial, which ended in a defense verdict for Bard after a jury rejected claims that a patient’s injuries were caused by a defective catheter.

Despite the outcome, the litigation continues to expand, with thousands of pending lawsuits alleging catheter fractures, migration, infections, and other PowerPort-related complications.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chat feature on this page to find out if you qualify in just minutes.

Medical device manufacturer Becton Dickinson and its Bard unit secured a defense verdict in the first Bard PowerPort bellwether trial, marking a significant development in the ongoing federal litigation involving allegedly defective chemotherapy port devices.

The first bellwether case focused on allegations that a Bard PowerPort device caused a serious infection after implantation.

The jury ultimately sided with Bard, rejecting claims that the device was defective in the plaintiff’s case.

The verdict represents an early setback for plaintiffs pursuing Bard PowerPort Lawsuits, which currently include more than 3,000 cases consolidated in federal multidistrict litigation (MDL).

Bellwether trials are used in multidistrict litigation to test how juries respond to evidence and legal arguments presented in representative cases.

Multidistrict litigation (MDL) is a federal legal procedure that consolidates similar lawsuits before one judge to streamline discovery, pretrial rulings, and case management.

Bellwether outcomes often influence settlement discussions, although a single verdict does not determine the outcome of remaining lawsuits.

At least four additional Bard PowerPort bellwether trials are scheduled through February 2027.

Upcoming cases are expected to focus on allegations involving catheter fracture and thrombosis injuries.

The court overseeing the Bard PowerPort MDL has also directed both parties to participate in settlement discussions scheduled for July 2026.

The Bard PowerPort litigation is entering an important stage as the first federal bellwether trial moves toward conclusion in Arizona federal court.

The case is being closely watched because it will likely shape settlement discussions and litigation strategy across more than 3,000 pending lawsuits involving alleged port catheter defects.

The first trial involves a plaintiff who alleges a Bard PowerPort caused a severe bloodstream infection that required hospitalization, surgical removal of the device, and delays in chemotherapy treatment.

Plaintiffs argue Bard knew for years that the catheter design carried elevated risks of infection, fracture, and migration but failed to adequately warn physicians or patients.

A major focus of the trial has been whether the device itself was defectively designed or whether the infection resulted from improper handling during at-home care.

Bard has argued the complication stemmed from outside contamination rather than any flaw in the catheter.

Plaintiffs, however, point to internal evidence and expert testimony alleging the polyurethane material used in the catheter may degrade over time, increasing the risk of cracks, bacterial entry, and device failure.

The litigation has continued to grow rapidly.

Recent reports indicate the MDL now includes more than 3,000 cases, with additional bellwether trials scheduled through 2027 involving claims of infections, thrombosis, and catheter fractures.

Because bellwether trials are designed to test how juries respond to common evidence and expert testimony, the outcome of this first case could significantly influence future Bard PowerPort settlement negotiations and the overall direction of the litigation.

A federal bellwether trial involving Bard’s PowerPort catheter is focusing on whether the company failed to adopt safer technologies that could have reduced infection risks, with Bard defending its design and testing decisions.

At trial, a former Bard research director testified that the company evaluated multiple antimicrobial coatings and other technologies but determined they were not safe or effective enough for patient use.

He stated that no clinically proven coating has been shown to reliably reduce infection rates in port catheters and that some alternatives introduced new risks, such as weakening the device or disrupting fluid flow.

Plaintiffs argue the company overlooked viable options that could have prevented infections, pointing to internal development efforts and regulatory submissions that were ultimately abandoned.

The case centers on whether Bard should have pursued additional testing or approval of antimicrobial designs that plaintiffs claim were feasible.

The dispute reflects core issues across the broader PowerPort litigation, particularly whether the device was defectively designed, whether safer alternatives were available, and whether the manufacturer exercised reasonable care in evaluating and implementing infection-prevention technologies.

The Bard PowerPort MDL added 143 cases between April and May, increasing from 3,044 to 3,187 cases pending.

The continued rise shows the steady increase of plaintiffs joining the litigation.

The first bellwether trial in the Bard PowerPort MDL is currently underway, with the plaintiff in the case alleging a serious infection caused by a Bard port resulted in hospitalization, delayed cancer treatment, and surgical removal of the device.

The outcome of initial bellwether trials in mass tort litigation often has a large impact on settlement discussions.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chat feature on this page to find out if you qualify in just minutes.

The first bellwether trial in the Bard PowerPort multidistrict litigation is underway, focusing on allegations that the implanted catheter device caused a severe infection leading to hospitalization, delayed cancer treatment, and surgical removal.

The plaintiff claims the manufacturer knew for years that the device carried elevated risks of infection but failed to improve the design or adequately warn patients and physicians.

At trial, evidence has focused on whether the device itself contributed to the infection or whether the complication resulted from how the catheter was handled during at-home care.

The defense argues the infection was caused by improper use outside a sterile environment rather than a product defect, highlighting a central dispute over causation.

In contrast, plaintiffs point to data and internal knowledge suggesting the device may have inherent risks that were not disclosed.

This bellwether trial is testing core issues across thousands of similar cases, including whether the catheter was defectively designed, whether infection risks were foreseeable, and whether adequate warnings and safety instructions were provided.

The outcome is expected to shape how juries evaluate liability and causation in the broader litigation.

Jury selection has begun in the first federal bellwether trial involving Bard PowerPort Lawsuits, marking a key procedural step in multidistrict litigation centered on allegations that the implantable catheter device caused serious infection and related complications.

Court filings state that proceedings are underway in the U.S. District Court for the District of Arizona, where the litigation is consolidated for coordinated pretrial proceedings.

The bellwether trial involves claims that a Bard PowerPort device manufactured by Becton Dickinson and its subsidiary C.R. Bard was defectively designed and increased the risk of infections, catheter fractures, and device migration.

Plaintiffs allege that these complications can lead to severe outcomes, including pulmonary embolism, blood clots, and the need for surgical removal or revision procedures.

Court records show that jury selection is scheduled to proceed with a narrowed pool of approximately 40 prospective jurors. The process includes voir dire, during which attorneys for both plaintiffs and defendants will question jurors to determine suitability for service.

The case represents the first of multiple bellwether trials planned to evaluate evidence and legal arguments across thousands of pending Bard PowerPort Lawsuits.

The first selected case involves a Minnesota plaintiff who allegedly suffered an infection linked to a Bard PowerPort implant.

A federal judge overseeing the Bard PowerPort multidistrict litigation has limited the ability of plaintiffs to reference prior issues involving Bard’s IVC filters during upcoming bellwether trials, narrowing the scope of evidence that can be presented to juries.

The ruling focuses on keeping the trials centered on the specific allegations involving PowerPort catheter devices, rather than allowing broader arguments based on the company’s history with other medical device litigation.

Courts often restrict this type of evidence to avoid unfair prejudice and ensure juries evaluate claims based on the facts tied directly to the product at issue.

The PowerPort litigation involves thousands of claims alleging that the implanted catheter devices are defectively designed and prone to complications such as fractures, infections, and migration within the body.

Plaintiffs allege the manufacturer failed to adequately warn about these risks and continued to market the devices as safe.

By limiting references to prior litigation, the court’s decision reinforces that upcoming bellwether trials will focus on whether the PowerPort devices themselves were defective and whether warnings and testing were sufficient, without introducing broader claims about unrelated products.

The Bard PowerPort MDL added 216 cases between March and April, increasing from 2,828 to 3,044.

This is a significant month-over-month increase in filings compared to prior months.

The court continues to oversee coordinated discovery and expert development, with no new JPML transfer activity reported during the month.

If you or a loved one has experienced serious complications after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chat feature on this page to find out if you qualify in just minutes.

A final pretrial conference has been scheduled for April 9, 2026, in the federal multidistrict litigation involving Bard PowerPort devices, marking the last major procedural step before the first bellwether trial begins later this month.

The conference will address remaining disputes over trial structure and finalize preparations for presenting the case to a jury.

One of the primary issues expected to be resolved is whether the trial will proceed in a bifurcated format, which would separate determinations of liability from damages.

Defendants have requested this structure, and the court’s decision may affect how evidence is presented and how the jury evaluates the claims.

The upcoming trial is the first bellwether case selected to help gauge how juries respond to allegations that Bard PowerPort devices are defectively designed and prone to complications such as catheter fracture, migration, and thrombosis.

Outcomes in these early trials are often used by both parties to assess litigation risk and inform potential settlement discussions.

Developments surrounding the second bellwether case may also impact the overall trial schedule.

The plaintiff in that case recently passed away, and a court imposed deadline requires the plaintiff’s estate to decide whether to proceed.

The decision may determine whether the case remains in the bellwether pool or is replaced.

The Bard PowerPort litigation currently includes thousands of claims consolidated in federal court.

Additional bellwether trials are expected to follow throughout 2026 and into 2027 as the court continues to evaluate representative cases.

The Bard PowerPort litigation added 154 cases between February and March, increasing from 2,674 to 2,828.

The rise reflects continued filings alleging that implanted port catheter devices fractured, migrated, or caused infections, thrombosis, and other serious complications.

The court continues to oversee coordinated discovery and pretrial proceedings within the federal multidistrict litigation.

The Bard PowerPort lawsuits focus on claims that the devices were defectively designed and that adequate warnings were not provided regarding catheter fracture and embolization risks.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

A plaintiff selected for an upcoming Bard PowerPort bellwether trial has passed away, creating uncertainty surrounding a summer 2026 trial date.

The deceased plaintiff was scheduled to proceed to trial on July 7, 2026.

A joint memorandum filed with the court disclosed that Miller entered hospice care in late January due to advanced cancer and died on February 2.

Counsel reported that Miller was unable to complete a preservation deposition before her death due to her medical condition.

Attorneys are consulting with Miller’s family to determine whether to open an estate and appoint a representative to continue the Bard PowerPort lawsuit.

The first federal Bard PowerPort bellwether trial remains scheduled for April 2026 and involves a different plaintiff.

The outcome of the initial Bard PowerPort bellwether trials may influence future settlement discussions and litigation strategy across the MDL.

Bellwether trials for Bard PowerPort catheter devices are scheduled to begin in 2026 as part of ongoing multidistrict litigation.

These cases will test claims that the catheters are prone to material degradation and fracture, potentially leading to serious complications including blood clots, embolism, infection, and emergency removal procedures.

The trials will provide evidence on device design, manufacturing practices, and the adequacy of warnings to physicians and patients.

Early verdicts are expected to influence settlement negotiations and may set precedents affecting the safety oversight of all implantable vascular access devices.

Plaintiffs allege the company failed to fully communicate known risks, while Bard maintains the devices are FDA‑cleared and asserts that clinicians are informed of potential complications.

The outcome of these trials could have implications for patient safety standards and regulatory oversight.

New lawsuits against Bard continue to highlight blood clot complications linked to the PowerPort catheter system.

Recent complaints allege that patients developed serious swelling and vascular issues years after implantation, with imaging later revealing blood clots forming around the catheter.

In several cases, the clotting required surgical removal of the device and additional medical treatment.

Plaintiffs say the PowerPort’s design increases the risk of thrombosis and that Bard failed to properly warn doctors and patients about these dangers, even after reports of clot formation, fractures, infections, and embolic events surfaced.

The claims argue Bard continued to market the device as safe for long-term use despite growing evidence of these risks.

These cases are now part of the federal Bard PowerPort MDL, where the court is preparing a bellwether trial group to assess how juries respond to evidence regarding catheter design, clot formation, and the manufacturer’s knowledge of these complications.

While the bellwether outcomes will not decide every case, they are expected to strongly influence settlement negotiations and the future course of the litigation.

A peer-reviewed case report has added new detail to safety concerns underlying Bard PowerPort lawsuits, describing a spontaneous catheter fracture that occurred only six months after implantation and led to fragment migration into a patient’s pulmonary artery.

According to a report published in the medical journal Cureus, the incident involved a 69-year-old cancer patient who required two procedures after part of a Bard port catheter broke and traveled through the bloodstream.

Central venous access ports, often called port catheters or port-a-caths, are implantable devices used to administer chemotherapy and provide long-term intravenous access.

The system includes a small reservoir placed beneath the skin and a catheter threaded into a central vein.

The Cureus authors reported that preoperative imaging showed the Bard port catheter in the proper position.

A chest X-ray taken shortly before removal later revealed that a segment of the catheter had already fractured and migrated into the left pulmonary artery.

Surgeons removed the port without recognizing the missing fragment.

A follow-up X-ray confirmed that a three-and-a-half-inch catheter piece remained lodged in a blood vessel, requiring a second same-day retrieval procedure.

The authors stated that catheter fracture and retained fragments are considered uncommon, especially after short implantation periods.

Medical literature has documented many fractures after devices remained implanted for several years.

The report described the six-month timeframe as unexpected and discussed mechanical stress between the collarbone and first rib, known as pinch-off syndrome, as a possible contributing factor.

The authors recommended reviewing recent chest imaging or ordering pre-removal X-rays in certain patients to reduce the risk of retained fragments.

The Bard PowerPort MDL added 129 cases between January and February, increasing from 2,545 to 2,674.

Filing activity accelerated compared to the prior month.

No significant JPML rulings or new docket developments were reported during the period.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

Operative findings describing tissue growth around retrieved catheter fragments are emerging as a key proof point in port and catheter litigation.

Surgeon notes using terms such as “endothelialized,” “encased,” “adherent,” or “surrounded by a fibrin sheath or fibrous tissue” are used to argue a fragment was not created during a recent procedure, but had been retained long enough for tissue to form around it.

Blood vessels are lined by endothelium, and when a foreign object remains in place, the body may deposit protein, clot material, and fibrous tissue that can become organized over time.

During retrieval, surgeons sometimes document fragments that are attached to the vessel wall, require added force to remove, are covered by a sheath-like layer, or appear embedded in tissue.

Medical literature supports these findings.

Radiology sources describe fibrin sheath formation beginning as early as 24 hours, with progressive coverage over time.

A 2025 open-access pathology study documents time-sequenced changes in catheter-related fibrin sheath development from early to later stages.

These observations are used to counter defense theories that fragments result from acute events such as access attempts, removal procedures, surgical mishaps, or high-pressure injections.

While endothelialization is not a precise timing tool, it functions as a biological indicator suggesting long-term retention, making a “recent breakage” explanation less persuasive.

Case literature confirms retained catheter fragments can remain in the body for years, and clinicians report removal difficulties consistent with long-term tissue integration.

Courts generally treat endothelialization-related operative notes as admissible medical records created in the normal course of care.

The primary dispute typically involves expert testimony and whether such findings can reliably support timing inferences.

Courts are more receptive when experts present endothelialization as time-consistent evidence rather than a specific calendar determination.

The first bellwether trial in the federal Bard PowerPort litigation is scheduled to begin on April 21, 2026, marking a significant milestone in the ongoing multidistrict litigation centralized in the U.S. District Court for the District of Arizona.

The trial will be the first jury test of claims alleging that Bard PowerPort implantable port catheter devices caused serious injuries due to defective design and manufacturing.

The Bard PowerPort MDL includes more than 2,500 lawsuits filed by plaintiffs nationwide.

These cases involve allegations that the devices are prone to catheter fractures, migration, bloodstream infections, thrombosis, and other complications.

Plaintiffs contend that the materials used in the catheter component, including polyurethane blended with barium sulfate, weaken the device and increase the risk of failure and infection.

The lawsuits further allege that the manufacturer failed to adequately warn physicians and patients about these risks.

The April 2026 trial is the first of six bellwether cases selected to proceed before juries through February 2027.

Bellwether trials are intended to evaluate representative claims and provide insight into how juries may respond to the evidence and legal arguments presented.

While the outcomes are not binding on other cases, they are expected to influence future settlement discussions and the overall direction of the litigation.

Pretrial proceedings remain ongoing, including expert discovery and motions challenging causation and admissibility of evidence.

If the bellwether trials do not result in a global resolution, additional cases may eventually be remanded to their original courts for individual trials.

The Bard PowerPort litigation continues to develop as the first trial date approaches, with bellwether outcomes expected to shape the path forward for thousands of pending claims.

The Bard PowerPort MDL added 82 cases between December and January, increasing from 2,463 to 2,545.

The filing increase reflects continued plaintiff intake following prior bellwether activity.

No major JPML filings or new docket developments were reported during this month.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

A federal appeals court has ruled that C.R. Bard cannot enforce several patents related to its implanted PowerPort medical devices, siding with competitor AngioDynamics in a long-running patent dispute.

The court agreed with a lower court that Bard’s patents were not valid because similar catheter ports already existed before Bard filed its patent claims. In other words, the court found that the ideas Bard tried to patent were not new.

At the center of the case were Bard’s claims that its ports could be identified on X-rays using special markers, which doctors rely on when injecting contrast dye at high pressure.

The court ruled that simply being visible on an X-ray is not a unique invention, since earlier ports already had shapes and features that doctors could see on imaging.

The judges also rejected Bard’s argument that using letters or symbols visible on X-rays made the device patentable.

The court said those markings only communicate information to doctors and do not change how the device actually works.

Because older catheter ports were already capable of handling high-pressure injections, even if they were not marketed that way, the court found that Bard’s patents were anticipated by earlier designs.

The decision wipes out a prior jury verdict that had favored Bard and ends Bard’s attempt to block AngioDynamics from selling competing implantable port devices.

Expert testimony on the degradation of polyurethane materials remains a key issue in the Bard PowerPort lawsuit, as courts continue to assess whether the implanted vascular access devices can chemically degrade under normal use conditions.

Plaintiffs’ experts in the Bard PowerPort litigation contend that the device’s polyurethane catheter is susceptible to oxidative degradation after implantation, a process they say weakens the material over time and increases the risk of cracking, fractures, and embolization within the body.

These opinions rely on materials science testing, including chemical analysis and mechanical stress evaluations, to argue that degradation can occur without misuse or excessive force.

Defendants, including C. R. Bard, dispute those conclusions, maintaining that the polyurethane used in the Bard PowerPort is stable in vivo and that any failures result from external factors such as improper access technique, patient-specific conditions, or off-label use.

Bard argues that the chemical breakdown theories lack real-world clinical support and overstate laboratory findings that do not reflect normal implantation conditions.

Courts overseeing the Bard PowerPort MDL have increasingly focused on whether materials science experts may testify about polyurethane degradation, including whether their methodologies meet federal admissibility standards.

Judges are scrutinizing how experts link chemical changes in polyurethane to actual device failures, and whether the testing reliably simulates the physiological environment over the lifespan of an implanted port.

These admissibility disputes are significant for the broader Bard PowerPort lawsuit, as expert opinions on material degradation go directly to core claims involving design defect, failure to warn, and causation.

Rulings on expert testimony are expected to shape the scope of evidence presented to juries and influence how individual Bard PowerPort cases move toward bellwether trials or resolution.

The Bard PowerPort MDL added 336 cases between November and December, rising from 2,127 to 2,463.

This marks the largest month-over-month increase recorded in this litigation to date.

The steady growth in the Bard PowerPort litigation points to ongoing interest from plaintiffs who allege injuries caused by fracturing or migration of the implanted port catheter.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

Judge David G. Campbell has finalized the schedule for the initial Bard PowerPort bellwether trials, scheduling six jury trials between April 2026 and February 2027.

The Court’s November 14 order shifts the first trial, initiated by Minnesota plaintiff Robert Cook, from March 2026 to April 21, 2026.

Additional trials are set for July 7, August 18, October 13, and December 1, with the final benchmark starting on February 2, 2027.

All six cases have finished the selection process and are in final preparations.

These trials will give juries the first chance to hear evidence about the alleged degradation of the device’s barium sulfate–filled catheter and the injuries linked to fractures and movement of the line.

Attorneys on both sides are closely monitoring the schedule, as early results will determine the next steps in the litigation and affect potential settlement talks.

If the bellwether trials fail to produce agreements that settle large parts of the MDL.

In that case, Judge Campbell has indicated he may start sending individual lawsuits back to federal courts across the country for separate trials.

The Bard PowerPort lawsuit saw a rise in case filings between October and November, increasing from 1,973 to 2,127.

This reflects continued interest in claims related to catheter device failures.

Plaintiffs report that the PowerPort can fracture or migrate, which may lead to serious complications such as infections, blood clots, or the need for revision surgery.

The steady increase in filings suggests ongoing concerns about device safety and continued legal activity in the MDL.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

Many Bard PowerPort implants, like other subdermal port catheters, become encased in a thick layer of fibrous tissue over time.

This biological response, known as capsule formation, is the body’s way of walling off foreign objects.

While medically common, this process can have serious implications for both patient care and litigation.

Encapsulation may obscure key signs of catheter failure.

For example, imaging scans might not detect a fractured catheter if the surrounding scar tissue holds the pieces in place.

This can delay diagnosis, mislead radiologists, or downplay the extent of device migration.

When PowerPorts are removed, the condition of the capsule matters.

Devices that are removed with the capsule intact can provide stronger forensic evidence.

Pathologists can examine tissue for signs of chronic inflammation, infection, or hidden fractures that would otherwise be missed.

For attorneys, this can strengthen arguments around product defect or latent injury.

From a legal standpoint, delayed symptom onset due to capsule coverage can also affect the statute of limitations.

Some plaintiffs may not realize their port fractured or migrated until years after symptoms began, raising issues of discovery and latent defects.

Considerations for patients and lawyers:

• Ask the surgeon to photograph the device in situ before removal.
• Request preservation of both the catheter and surrounding capsule tissue.
• Confirm that pathology documents the thickness and composition of the fibrous capsule.
• Ensure explanted materials are properly packaged and labeled for expert analysis.

Because Bard PowerPorts are still implanted in many patients and remain unrecalled, these issues will continue to arise in new cases.

Capsule formation isn’t just a medical side effect, it’s a critical factor in how PowerPort complications are detected, diagnosed, and proven in court.

The Bard PowerPort lawsuit remained virtually unchanged between September and October, with total cases moving from 1,972 to 1,973.

This one-case increase suggests the litigation is holding steady, with no significant uptick or slowdown in new filings at this time.

Plaintiffs in these cases allege that Bard’s implantable port devices fractured or migrated, leading to serious internal injuries and infections.

The consistency in numbers may reflect a pause as cases await pretrial rulings or potential settlement developments.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

As of September 2025, more than 2,100 lawsuits have been centralized in the Bard PowerPort multidistrict litigation (MDL No. 3081) in the U.S. District Court for the District of Arizona, overseen by Judge David G. Campbell.

These cases raise similar allegations that design defects in Bard’s implantable port catheter caused severe injuries due to catheter fractures, migration, and related complications.

Key Litigation Developments:

• The Bard PowerPort MDL was formed in July 2023 to streamline discovery and pretrial proceedings.
• The lawsuits claim that Bard’s port catheters, often used for chemotherapy or long-term medication delivery, suffer from design flaws that allow pressure buildup and structural failure.
• Plaintiffs allege these failures caused life-threatening injuries and that Bard knew or should have known about the risks but failed to act.

Bellwether Trials Scheduled for 2026

• The Court has selected six bellwether cases for early trial, beginning with a lawsuit filed by Robert Cook scheduled for trial on March 2, 2026.
• Additional federal trials are planned throughout 2026.
• Separately, Arizona’s first state court trial is set for August 3, 2026.

Concerns Over Product Identification

Defendants have raised concerns that some complaints fail to properly identify the specific port device implanted.

Plaintiff leadership responded by noting that only six such cases lack product ID and were largely filed by the same firm.

This issue remains a point of contention as the litigation progresses.

Additional State Filings

• 146 lawsuits are pending in New Jersey’s multicounty litigation.
• 21 more cases have been filed in Maricopa County, Arizona.

While bellwether trial results are not binding, they are expected to significantly influence future settlement discussions.

If no global resolution is reached, Judge Campbell may remand individual cases back to their home districts for trial.

The Bard PowerPort litigation saw a steady rise in case filings last month.

As of September, 1,972 lawsuits have been consolidated in the multidistrict litigation (MDL), up from 1,807 in August.

The lawsuits, centralized in the District of Arizona, allege that Bard’s implantable port devices are prone to fracture, migrate, or cause serious infections and vascular injuries.

These defects have reportedly led to severe complications for patients who relied on the devices for long-term treatment, including chemotherapy and nutrition support.

If you or a loved one has experienced a complication after receiving a Bard PowerPort, you may qualify for legal action.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

The U.S. District Court for the District of Arizona has issued a case management order setting trial dates in the Bard PowerPort multidistrict litigation (MDL).

The litigation consolidates more than 1,800 Bard PowerPort lawsuits, which allege that the implantable port catheter devices were defectively designed and caused infections, fractures, and migration injuries.

The Bard PowerPort is a totally implantable vascular access device (TIVAD) marketed by Becton Dickinson and its subsidiary C.R. Bard. It is commonly used to administer chemotherapy and other repeated injections.

Plaintiffs claim the polyurethane catheter tube and port design made the devices unreasonably dangerous, resulting in serious complications that required revision surgeries and delayed treatments.

Judge David G. Campbell is overseeing the MDL and established a bellwether process to evaluate representative cases.

The purpose of bellwether trials is to test key evidence and expert testimony in front of juries, providing guidance for potential global Bard PowerPort lawsuit settlements.

The first trial is scheduled to begin on March 2, 2026, involving plaintiff Robert Cook of Minnesota.

Cook alleges his Bard PowerPort became infected within a week of implantation, forcing removal while he was undergoing chemotherapy.

Five additional trials are scheduled throughout 2026:

• Wanda Miller: April 27, 2026

• May Lattanzio: July 7, 2026

• Kimberly Divelbliss: August 17, 2026

• Judy Hicks: October 13, 2026

• Lloyd Sorenson: December 1, 2026

While the bellwether trial outcomes will not be legally binding on other Bard PowerPort lawsuits, they are expected to influence settlement negotiations.

Lawsuits continue to mount against Bard over its PowerPort implantable catheter systems, with plaintiffs alleging that defective design and materials have led to severe infections, blood clots, and life-threatening injuries.

The Bard PowerPort is used for long-term vascular access, often in cancer patients undergoing chemotherapy.

However, the device’s polyurethane and barium sulfate composition (intended to enhance imaging) has been linked to surface degradation, cracks, and bacterial buildup.

Lawsuits claim these structural weaknesses allow bacteria to colonize inside the catheter, leading to catheter-related bloodstream infections, sepsis, and the need for surgical removal.

As of August 2025, more than 1,800 Bard PowerPort lawsuits have been consolidated into MDL No. 3081 in the District of Arizona.

The first bellwether trial is scheduled for February 2026, involving a plaintiff who developed a serious infection and required revision surgery after receiving the device.

Plaintiffs also argue that Bard failed to implement safer design alternatives and failed to adequately warn users and doctors of the infection risks.

Despite growing evidence of surface degradation and bacterial colonization risks, Bard has not recalled the PowerPort.

The Bard PowerPort MDL added 44 new cases between July and August, bringing the total to 1,807.

Plaintiffs continue to allege that the implanted port devices fracture or degrade, releasing catheter fragments into the bloodstream.

These filings follow recent updates to case management orders and ongoing pretrial coordination in the District of Arizona.

If you or a loved one has experienced a complication after receiving a Bard PowerPort—even if it’s not listed above—you may still qualify for legal representation.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

A federal judge has selected the first bellwether trial in the Bard PowerPort multidistrict litigation (MDL), with proceedings expected to begin in February 2026.

The trial involves plaintiff Robert Cook, who alleges that he developed a serious infection one week after receiving a Bard PowerPort catheter in August 2022.

His lawsuit claims the device was defective and that Bard failed to warn about known risks.

The MDL, centralized in the U.S. District Court for the District of Arizona, includes more than 1,700 product liability lawsuits.

Plaintiffs allege that Bard PowerPort devices are prone to infections, catheter fractures, migration, and other complications due to design and material defects.

The lawsuits claim Bard, a subsidiary of Becton Dickinson, concealed these risks from medical providers and the public.

Six cases have been selected for early bellwether trials. They include three infection-related cases, two involving thrombosis, and one fracture case.

The selected cases involve various PowerPort models, including polyurethane, silicone, and Groshong devices.

These trials are intended to help gauge how juries may respond to evidence and legal arguments, and potentially guide future settlement discussions.

Judge David Campbell has scheduled a status conference for August 15, 2025, with a deadline of August 13, 2025, for the parties to propose a trial schedule.

If no global resolution is reached following the bellwether trials, remaining cases may be remanded to their original jurisdictions for individual trials.

Barium sulfate, a radiopaque agent, is blended into the polyurethane mixture of Bard’s PowerPort catheter to make it visible on X-rays.

However, lawsuits allege that Bard’s manufacturing process used an excessive concentration of uncoated barium sulfate, which does not bond uniformly with the polymer.

This can lead to microscopic clusters of barium sulfate forming weak points in the catheter wall.

Over time, bodily stresses (such as blood flow, pressure from injections, and natural movement) cause these weak areas to degrade.

As the polyurethane matrix erodes around the barium sulfate clusters, the surface becomes porous and brittle, increasing the risk of fracture, catheter embolization, infection, and blood clots.

Some studies have found loose barium sulfate particles shed from the catheter into the bloodstream, further compounding the danger.

Lawsuits claim that Bard was aware of these structural vulnerabilities but failed to warn patients and providers or adopt safer formulations using coated barium sulfate, which adheres more securely to the polymer base.

The Bard PowerPort MDL saw a significant increase in between June and July, growing from 1,500 to 1,763 cases—a monthly jump of 263 new filings.

This marks one of the largest single-month case increases in the litigation to date.

Discovery is progressing as the court evaluates technical evidence and company communications related to the PowerPort’s design and safety risks.

The surge in filings may pressure the parties to accelerate discussions around bellwether case selection or potential early resolution pathways.

If you or a loved one has experienced a complication after receiving a Bard PowerPort—even if it’s not listed above—you may still qualify for legal representation.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

If you or a loved one experienced complications from a Bard PowerPort device, reporting the injury to the FDA is a critical step.

These reports help federal regulators monitor medical device safety and can lead to future safety alerts, recalls, or investigations.

The FDA’s MedWatch program allows consumers, patients, and healthcare providers to submit voluntary reports of adverse events.

Steps to File a MedWatch Report:

1. Visit the MedWatch Reporting PageGo to the FDA MedWatch Online Voluntary Reporting Form.
2. Choose the Appropriate FormUse Form FDA 3500 for voluntary consumer or patient reporting
3. Fill Out Required InformationBe prepared to include:
   • Details about the device (Bard PowerPort model, if known)
   • Description of the injury or complication
   • Date of the incident
   • Medical treatment received
   • Healthcare facility involved
4. Attach DocumentationIf possible, upload supporting documents such as:
   • Medical records
   • Photos of the injury or device
   • Discharge summaries
5. Submit the ReportReview the form for accuracy and submit it directly through the FDA website.

Why Reporting Matters

Each report contributes to a growing database of medical device safety concerns.

The FDA reviews these submissions for trends that may indicate product defects or public health risks.

Submitting your report may help protect others from similar harm.

If you or a loved one suffered injuries related to the Bard PowerPort Device, our law firm can help you seek compensation and justice. 

Contact us today for a free consultation. 

Use the chat feature on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly. 

The Bard PowerPort MDL grew by 90 cases between May and June, bringing the total to 1,500 Bard PowerPort Lawsuits filed in federal court.

Many recent filings include detailed medical records linking device breakage to emergency port removal and hospitalization.

Bard PowerPort Lawyers continue to push for early bellwether selection, citing the volume of cases involving nearly identical product failure modes.

If you or a loved one has experienced a complication after receiving a Bard PowerPort—even if it’s not listed above—you may still qualify for legal representation.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

Six bellwether trial cases and one alternate have been selected in the Bard PowerPort MDL.

In December 2023 both plaintiffs and defendants were instructed by the court to nominate six representative cases.

Initial agreement was reached on only two cases, but further negotiation resulted in consensus on three.

The court independently selected the remaining cases based on data, including the nature and severity of alleged injuries.

The first Bard PowerPort bellwether trial is expected to begin in 2026, three years after the MDL was formed.

These early trials will serve as a test for how juries may respond to recurring allegations that Bard’s implantable port devices are prone to fracturing and causing serious medical complications.

The outcome of the bellwether trials could significantly shape potential future settlements or resolutions in the growing number of Bard PowerPort Lawsuits.

On May 12, U.S. District Judge David G. Campbell selected six Bard PowerPort lawsuits and one alternate to proceed as the first bellwether trials in the federal court MDL.

The selected cases represent a cross-section of injury types and device models involved in more than 1,400 claims consolidated in the District of Arizona.

The selections include three infection-related cases, two involving thrombus injuries, and one involving a fracture.

The types of devices include four polyurethane devices, one silicone device, and one Groshong catheter.

Judge Campbell overruled the decisions of three parties, citing inadequate representation across the broader litigation, and replaced them with cases he considered more proportional.

The final lineup includes lawsuits filed by Wanda Miller, Robert Cook, Judy Hicks, Kimberly Divelbliss, May Lattanzio, and Lloyd Sorensen.

Peter James’s case was selected as an alternate.

These early trials will explore how juries respond to ongoing allegations that Bard PowerPorts degrade and fail within the body, resulting in infections, thrombosis, catheter fractures, and, in some cases, necessitating surgical intervention.

The outcomes may influence settlement discussions but are not binding in other cases.

The Bard PowerPort lawsuit involves claims that the implanted port catheter device has caused serious complications, including infections, device fractures, and blood clots.

Plaintiffs allege that Bard failed to adequately warn patients and healthcare providers about these risks.

205 cases have been added to the Bard PowerPort MDL in the past month.

This growth has been consistent throughout this year, with 519 cases added to the litigation since January 1st.

These complications may require invasive medical intervention and can lead to long-term health consequences for affected individuals.

If you or a loved one has experienced a complication after receiving a Bard PowerPort—even if it’s not listed above—you may still qualify for legal representation.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

Want to find out if you qualify for the Bard PowerPort Lawsuit right now? 

You can use the chatbot on this page to find out if you qualify in just minutes.

Law firms nationwide are continuing to receive inquiries from individuals who believe they’ve been harmed by the Bard PowerPort implantable port device.

The current lawsuit cases involve a range of reported injuries and complications, but may not include all claims against Bard PowerPort.

To help affected individuals understand whether they may qualify for legal action, we are providing the most up-to-date criteria for currently accepted injuries in the Bard PowerPort lawsuit.

As of April 2025, the following injuries are most commonly being accepted in active litigation:

• Catheter Fractures: The catheter portion of the Bard PowerPort may crack or break, potentially releasing fragments into the vascular system.
  • These fragments can migrate, causing internal injury or requiring surgical intervention.
• Device Migration: In some cases, the device or its components may shift from their intended position, which can result in damage to blood vessels or nearby organs.
• Infections: The implantation or long-term use of the PowerPort may introduce bacteria or other pathogens into the body, leading to localized or systemic infections that may require hospitalization or additional treatment.
• Thrombosis: Blood clots can develop around the catheter tip or along the length of the catheter, increasing the risk of embolism or vascular blockage.
• Cardiac Complications: Though rare, some patients have reported that fractured catheter pieces reached the heart, leading to arrhythmias, perforations, or other serious cardiac events.

It’s important to note that the list of accepted injuries in this litigation is continually evolving as new information and reports emerge.

If you or a loved one has experienced a complication after receiving a Bard PowerPort—even if it’s not listed above—you may still qualify for legal representation.

For those experiencing complications, it is strongly recommended to consult with an attorney for a free case review.

The Bard PowerPort litigation saw a notable increase in filings from March to April 2025.

In March, there were 1,112 total new cases filed, while in April, the number of filings rose to 1,205, reflecting an increase of 93 new cases.

This rise in filings indicates continued legal action being taken by individuals who have experienced harm due to the Bard PowerPort device.

The ongoing litigation suggests that more affected individuals are coming forward to join the multidistrict litigation, seeking compensation and accountability from the manufacturer.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort lawsuit involves claims that the implanted medical device, used for long-term venous access, has caused severe complications such as infections, device fractures, and blood clots.

Plaintiffs allege that Bard failed to adequately warn patients and healthcare providers about these risks.

In February, 1,004 cases were pending in the Bard PowerPort MDL.

The number of pending Bard PowerPort Lawsuits has increased to 1,112 in March, with 108 new claims added.

Device fractures and infections can lead to life-threatening conditions, requiring additional medical interventions and posing serious risks to patient health.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The U.S. District Judge overseeing the Bard PowerPort litigation has directed lawyers involved in the case to submit a joint proposal by March 18, 2025, outlining their plans to prepare the first round of bellwether test cases.

These early trials will help determine how juries may respond to common allegations raised in the more than 1,000 lawsuits filed against C.R. Bard and Becton Dickinson & Company, the manufacturers of the PowerPort implantable vascular access device.

The lawsuits primarily claim that the devices are prone to degradation, leading to fractures, infections, and the need for revision surgeries.

The bellwether trials will serve as a tool to assess how juries react to evidence, which may influence the settlement process for future cases.

Since the lawsuits were consolidated into a multidistrict litigation (MDL) in August 2023, 24 cases were initially selected for discovery, and that number has since been narrowed down to 15 eligible for trial. 

The final selection of six bellwether cases will be determined by mid-April 2025, with a case management conference set for March 20 to discuss specific schedules and motions.

While the outcomes of these trials will not be binding for all claims, they will significantly influence the future direction of the litigation and settlement negotiations.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort Lawsuit involves claims that the implanted medical device, used for long-term venous access, has caused severe complications such as infections, device fractures, and blood clots.

Plaintiffs allege that Bard failed to adequately warn patients and healthcare providers about these risks.

891 cases were pending in the Bard PowerPort MDL at the beginning of the year, increasing to 1,004 in February, with 113 new claims added.

This rise reflects growing awareness and legal action from individuals experiencing complications linked to the Bard PowerPort device.

Device fractures and infections can lead to life-threatening conditions, requiring additional medical interventions and posing serious risks to patient health.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort lawsuit involves claims that the implanted medical device, used for long-term venous access, has caused severe complications such as infections, device fractures, and blood clots.

Plaintiffs allege that Bard failed to adequately warn users about these risks.

In December, 813 cases were pending in the Bard PowerPort MDL.

The number of pending cases has increased to 891 in January, with 78 new claims added.

This growth highlights ongoing concerns among patients about the health risks linked to the Bard PowerPort device.

Complications from the Bard PowerPort can result in life-threatening conditions requiring medical intervention, significantly impacting the well-being of affected individuals.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

Lawyers involved in the Bard PowerPort multidistrict litigation (MDL) have identified 15 cases for additional fact discovery, moving closer to early bellwether trials.

These lawsuits allege the Bard PowerPort, a vascular access device used for delivering chemotherapy and other medications, was defectively designed, leading to severe complications like catheter fractures and infections that often require surgical removal.

The MDL, centralized in the District of Arizona under U.S. District Judge David G. Campbell, currently includes over 800 Bard PowerPort Lawsuits.

To assess the strength of claims and how juries may respond to evidence, Judge Campbell has called for bellwether trials.

Initially, 24 cases were selected in December 2023 for case-specific discovery, which has now been narrowed to 15.

The parties must identify six of these cases by early March 2025 for the first trial dates.

However, a joint motion has requested an extension until April 2025, citing the need to incorporate expert disclosures into their selection process.

If the parties cannot agree on the six cases, competing proposals will be submitted by April 14, 2025.

While the outcomes of these trials will not bind other claims, they are expected to influence settlement negotiations and shape the trajectory of the litigation, potentially avoiding hundreds of individual trials in the future.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The U.S. District Judge overseeing all federal Bard PowerPort lawsuits is meeting today with attorneys involved in the litigation to review its progress and discuss the next steps, as the number of cases continues to grow rapidly.

This litigation centers on allegations that the Bard PowerPort, a totally implantable vascular access device (TIVAD) designed for delivering chemotherapy and other medications, was defectively designed.

The device, which includes an injection port and a polyurethane catheter tube, is marketed as being able to withstand high injection pressures. .

The Bard PowerPort litigation has nearly doubled in size over the past three months as more individuals become aware that their injuries may be linked to the device’s faulty design. 

To manage these claims, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established a Bard PowerPort MDL in August 2023, centralizing the lawsuits before U.S. District Judge David G. Campbell in the District of Arizona for coordinated pretrial proceedings.

By December 10, both sides will exchange lists of five cases for inclusion in a Discovery Group, with an additional five cases to be jointly identified and finalized by December 18.

This will narrow the pool to 15 cases, which will undergo further discovery before being reduced to six bellwether cases by March 2025. 

These six cases will proceed to early jury trials, aimed at gauging potential settlement values and providing insight into the average payouts for Bard PowerPort claims.

Although the outcomes of these bellwether trials will not directly affect the remaining lawsuits, they are expected to play a critical role in shaping settlement negotiations.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort Implanted Port Catheter lawsuits involve claims that the device, used for long-term venous access, has caused severe complications such as infections, device fractures, and blood clots.

In November, 720 cases were filed, increasing to 813 in December, with 93 new claims added.

This growth reflects heightened awareness of the risks associated with the Bard PowerPort device.

These complications can lead to significant medical issues, including life-threatening conditions requiring extensive medical intervention.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The federal Bard PowerPort Lawsuits are progressing on a strict timeline as the presiding judge declined a request to extend discovery deadlines.

Parties must complete all depositions and fact discovery by January 2025, keeping cases on track for early bellwether trials.

These lawsuits, now exceeding 700 claims, involve allegations of severe complications linked to the Bard PowerPort, a vascular access device used for administering chemotherapy and other treatments.

Plaintiffs report issues such as catheter fractures and infections, which they attribute to design defects.

The litigation was centralized into a multidistrict litigation (MDL) in August 2023 to streamline pretrial proceedings.

As part of this process, 24 bellwether cases were selected for focused discovery to assess the strengths and weaknesses of claims before juries.

Despite plaintiffs citing scheduling challenges due to holidays, the court has insisted on maintaining the January 2025 deadline, ensuring timely progression toward selecting six bellwether trials by March 2025.

These trials, expected to begin in late 2025 or early 2026, are pivotal for shaping settlement discussions and gauging jury reactions to key evidence.

The next case management conference, scheduled for December 3, 2024, may revisit the deadlines if further challenges arise.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort Lawsuit involves claims that the medical device, used for long-term venous access, has caused severe complications, including infections, device fractures, and blood clots.

Plaintiffs allege that Bard failed to properly warn patients and healthcare providers about these risks, leading to serious health issues for those relying on the PowerPort.

In October, there were 521 cases filed in connection with the Bard PowerPort.

By November, this number rose significantly to 720, adding 199 new cases.

This increase suggests that more patients are recognizing the potential dangers associated with the device and seeking legal recourse.

Complications linked to the Bard PowerPort can lead to life-threatening conditions such as sepsis, embolisms, and organ damage, impacting patients who depend on the device for essential treatments.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

A New Litigation has been Created for a Similar Device to the Bard Powerport. 

The AngioDynamics, Inc., and Navilyst Medical, Inc., Port Catheter Products Liability Litigation has been centralized in the Southern District of California.

The litigation focuses on allegations that these companies’ port catheter products are prone to degradation, fractures, and migration.

These defects reportedly lead to serious health risks, such as infections, blood clots, and perforations.

Multiple cases across 28 districts are now consolidated in this MDL.

The centralization of these cases is expected to streamline pretrial proceedings, reduce duplicative discovery, and prevent conflicting rulings.

While the defendants opposed centralization, citing the uniqueness of individual cases and product lines, the panel concluded that the common issues regarding product design, manufacturing, and safety warnings justified consolidation.

This consolidation marks a significant step forward for plaintiffs seeking justice for injuries caused by defective AngioDynamics and Navilyst Medical port catheter devices.

The Bard PowerPort Lawsuit is also ongoing, and our lawyers are accepting new cases related to Bard devices.

If you or a loved one have been injured by a Bard PowerPort Device or AngioDynamics Port Catheter device, you may be eligible to file a lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a lawsuit instantly.

The Bard PowerPort Implant Lawsuit involves claims that the medical device, designed for patients requiring long-term vascular access, has led to severe complications, including infections, device fractures, and blood clots.

The lawsuit asserts that the device was defectively designed, leading to these complications, and that the manufacturer, Bard, failed to adequately warn patients and healthcare providers about these risks.

In September, 427 cases were filed in connection with the Bard Powerport Implant recall.

By October, that number increased to 521, reflecting an additional 94 cases.

The complications from the Bard PowerPort Implant can be devastating.

Infections caused by the implant can lead to sepsis, which may result in long-term damage or death.

Device fractures, another common issue, can cause parts of the port to break off and migrate through the bloodstream, leading to further injuries such as embolisms or organ damage.

If you or a loved one were injured by Bard PowerPort devices, you may be eligible to file a Bard PowerPort Lawsuit against the medical device manufacturer.

Contact TorHoerman Law for a free consultation.

You can also use the chatbot on this page to find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard Powerport Implant lawsuit has seen a significant increase in filings from 336 in August to 427 in September.

The Bard PowerPort Implant, used for administering medications and fluids, has been linked to serious complications, including infections, device fractures, and deep vein thrombosis (DVT).

These issues have prompted numerous lawsuits from patients who allege that the device’s defective design has led to life-threatening conditions and additional medical treatments.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

As of August 2024, over 460 lawsuits have been filed against Bard, the manufacturer of the PowerPort, a totally implantable vascular access device (TIVAD) used for delivering chemotherapy and other medications directly into a patient’s bloodstream.

These cases are spread between Federal Multidistrict Litigation (MDL) and state courts in New Jersey and Arizona.

The lawsuits allege that the Bard PowerPort and other Bard port catheter devices were defectively designed, leading to severe and life-threatening complications, including fractures in the port catheters and the development of infections due to cracks in the material.

The federal litigation, which began in August 2023, has rapidly expanded. 

Of the federal cases, 172 are eligible for bellwether selection, with the first trials potentially starting in late 2025 or early 2026. 

As of now, there are 416 cases pending in the MDL in the District of Arizona, with an additional 50+ cases in state courts.

Judge David G. Campbell, overseeing the MDL, has reappointed the group of attorneys leading the plaintiffs’ efforts until September 2025.

In New Jersey, with 49 cases pending, a request was made in May 2024 to consolidate these cases before one state-court judge, similar to the federal MDL.

The next case management conference is scheduled for October 3, 2024, where further updates on the progress of bellwether cases and ongoing discovery disputes will be discussed.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort Lawsuit involves claims against Bard for its PowerPort device, which is alleged to cause serious injuries and complications.

Plaintiffs argue that design and manufacturing defects in the PowerPort have led to various health issues.

In July, there were 299 cases pending in the Bard PowerPort MDL.

This number rose to 336 filings by August 1st.

The Bard PowerPort is designed to facilitate the delivery of medication and other treatments.

However, defects in the device have been reported to cause complications such as infections, blood clots, and device fractures.

These complications can lead to severe health issues and necessitate additional medical interventions.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The U.S. District Judge presiding over all federal Bard PowerPort Lawsuits has selected 24 cases for case-specific discovery.

These bellwether claims will be prepared for early trials to gauge jury responses to evidence and testimony, influencing over 300 other pending lawsuits.

Each lawsuit involves allegations that the Bard PowerPort, a totally implantable vascular access device (TIVAD), was defectively designed, leading to severe infections, fractures, and other complications.

The device is used for delivering chemotherapy and other medications directly into a patient’s vascular system.

Plaintiffs claim the catheter material degrades over time, causing bacterial growth (infection, migration, and fracture, potentially leading to serious and life-threatening injuries.

In August 2023, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized Bard PowerPort Lawsuits into an MDL in the US District Court for the District of Arizona.

As of July 2024, there are 322 cases pending in the MDL, with additional claims filed in New Jersey state court.

Plaintiffs in the 24 selected cases must submit detailed Fact Sheets by July 31, 2024.

These sheets will provide written answers to a series of questions, forming the basis for subsequent discovery actions.

A status conference is scheduled for August 16, 2024, to review progress and discuss next steps.

Successful trials could prompt settlement discussions and negotiations, potentially resolving a large number of claims.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort lawsuit involves claims related to the Bard PowerPort, a medical device used for long-term medication delivery.

The lawsuit alleges the device is prone to fracturing and migration, causing serious health complications.

In June, there were 232 Bard PowerPort lawsuit filings, by July this number increased to 299.

The Bard PowerPort can cause severe complications when it fractures or migrates.

Patients have reported infections, blood clots, and the need for additional surgeries.

These issues have led to more individuals joining the Bard PowerPort lawsuit.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

The number of filings in the Bard powerport lawsuit increased from 189 in May to 232 in June, with 43 new cases sent to the MDL.

Patients implanted with the Bard PowerPort have reported severe complications from the device, including infection, thrombosis, and catheter migration, among other injuries.

Such issues not only pose serious health risks but also lead to increased medical costs and emotional distress for affected individuals.

Individuals experiencing health problems from the Bard Power Port device are encouraged to reach out to a lawyer to understand their legal options.

Our Bard PowerPort Lawyers are experienced in medical device litigation and can provide guidance to patients who have been injured.

If you or a loved one have been injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek financial compensation.

Contact a PowerPort injury lawyer from TorHoerman Law for a free, no-obligation case consultation.

You can also use our chatbot below to receive a free, instant online case evaluation and find out if you qualify for a Bard PowerPort Lawsuit instantly.

Significant procedural developments were discussed in the sixth Case Management Conference for the Bard PowerPort Lawsuit on May 10, 2024.

The conference set the stage for further actions and deadlines impacting all parties involved.

A seventh Case Management Conference is scheduled for May 24, 2024.

By May 22, 2024, all parties are required to file a joint memorandum updating on various issues as stipulated in the order from the recent conference.

Key developments include:

• Document Production: The parties have set completion deadlines for document production from non-custodial sources like Master Control, EasyTrack, and Veeva Vault Clinical, with deadlines ranging from June 17 to August 30, 2024.
  • The deadline for DocuShare documents remains to be determined.
• Successor Liability: Discussions are anticipated on a potential stipulation regarding successor liability aimed at minimizing discovery needs.
  • This is expected to be addressed comprehensively within the next 30 days.
• Discovery Scope and Costs: Concerns about the proportionality of the volume of documents retrieved by search terms were raised.
  • Both parties have agreed to confer further on the scope and financial implications of discovery, with detailed positions to be outlined in the impending joint memorandum.
• Compliance with Plaintiff Profile Forms: Several cases have been highlighted for non-compliance with required Plaintiff Profile Forms (PPFs), affecting their inclusion in the Initial Plaintiff Pool for bellwether cases.
  • Updates on these are due by the next conference.
• Medical Records and Deficiency Notices: Concerns were also noted regarding the completeness of medical records and other required documents, with several plaintiffs identified as having inconsistencies in their submissions.
  • Specific deadlines for resolving these issues have been set for May 23, 2024.

If you or a loved one has been injured by a Bard PowerPort device, contact us today for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

A total of 189 Bard PowerPort Lawsuits are now pending in multidistrict litigation according to the most recent JPML filings.

More than seventy cases were added to the litigation over the past month.

The Bard PowerPort is a type of implanted port used for the administration of medications, chemotherapy, and other procedures requiring access to a patient’s vascular system.

C.R. Bard is a subsidiary of Becton, Dickinson and Company.

The lawsuits allege that Bard Ports have design flaws that increase the risk of infection, thrombosis, and other serious complications.

Patients who have received a Bard Power Port implant have reported significant health problems potentially linked to the device.

Increasing awareness of these potential complications has prompted patients who’ve been injured to file claims.

If you or a loved one has been injured by a Bard PowerPort device, contact us today for a free consultation. You can also use the chatbot on this page for an instant case evaluation. 

On March 29, 2024, the U.S. District Court for the District of Arizona presided over the fifth Case Management Conference for the Bard Implanted Port Catheter Products Liability Litigation (MDL No. 3081).

During this session, significant procedural adjustments and order revisions were made.

Key Proceedings and Decisions include:

1. Document Sealing: Approval was granted for the sealing of specific documents, with a stipulation for redacted versions to be made public by April 12, 2024.
2. Case Management Protocols:
   • Deposition Guidelines: The court set a seven-hour limit for depositions, specifying time allocations to streamline testimony collection.
   • Discovery Updates: Agreements were reached on a technology-assisted review for document production, with initial deadlines set for July 1, 2024. The aim is to enhance efficiency in evidence handling.
3. Bellwether Trials: The timeline for bellwether selections remains as previously scheduled, maintaining the litigation’s momentum.
4. Profile Form Compliance: Emphasis was placed on the necessity of fully completing both Plaintiff and Defendant Profile Forms to ensure procedural fairness.

The next Case Management Conference is scheduled for May 10, 2024, via Zoom, where ongoing litigation activities and adherence to the new protocols will be assessed.

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

Per the latest JPML filings, there are currently 116 Bard PowerPort cases pending consolidation.

This indicates that ten cases were added to the Bard PowerPort MDL over the past month.

The Bard PowerPort, a type of implantable port used for long-term intravenous treatments, has been the focus of scrutiny and legal action.

Plaintiffs in these cases are alleging that defects in the design and manufacturing of the Bard Power Port devices have resulted in serious health complications.

If you or someone close to you has experienced health issues that may be related to the use of a Bard PowerPort, contacting a lawyer could be a crucial step to seeking compensation and justice.

For a free legal consultation to discuss your situation, please reach out to our team.

You can also use the chatbot on this page for immediate assistance and a free case evaluation.

The total number of cases pending in the Bard PowerPort MDL rose from 99 to 106 over the past month, according to the most recent JPML filings.

Seven new Bard PowerPort cases were transferred into the MDL during the past month.

Multidistrict litigations (MDLs), such as the Bard PowerPort litigation, are crucial mechanisms within the U.S. legal system.

MDLs are designed to efficiently manage civil lawsuits that share common issues.

This is particularly common in cases that relate to product reliability, pharmaceuticals, and mass tort actions, such as Bard PowerPort.

By consolidating related lawsuits into a single federal district court for pretrial proceedings, MDLs help streamline the litigation process.

The Bard PowerPort device, at the center of these lawsuits, has reportedly injured multiple individuals, prompting legal action.

If you or someone close to you has been injured by a Bard PowerPort device, it may be possible to join the ongoing litigation by filing a Bard PowerPort Lawsuit claim.

The chatbot available on this page offers an instant qualification check for the Bard PowerPort Lawsuit.

Currently, a total of 99 Bard PowerPort Lawsuits are pending consolidation according to the most recent JPML filings.

Multi-District Litigations (MDLs) are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.

When numerous individuals or entities file lawsuits related to a common set of circumstances, such as product liability, pharmaceuticals, or mass tort cases, these cases can be consolidated into a single federal district court for pretrial proceedings.

MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

Currently, there are a total of 69 filings in the Bard Implanted Port Catheter Products Liability Litigation, according to the most recent JPML filings published on January 2nd.

Bard PowerPort Lawsuits are being consolidated into multidistrict litigation (MDL).

MDLs are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.

When numerous individuals or entities file lawsuits related to a common set of circumstances, such as product liability, pharmaceuticals, or mass tort cases, these cases can be consolidated into a single federal district court for pretrial proceedings.

As patients across various jurisdictions have filed lawsuits alleging harm from the Bard PowerPort, these cases share common factual questions about the device’s safety, design, manufacturing processes, and the potential negligence of the manufacturer, Bard Access Systems Inc.

For individuals affected by the Bard PowerPort device, MDL offers a structured pathway to seek compensation and justice, ensuring that their cases are handled efficiently while still preserving the unique aspects of each individual claim.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

Judge Campbell has recently issued a set of six Case Management Orders that outline the rules and procedures for the next 18 months of the MDL involving Bard PowerPort lawsuits in the Eastern District of North Carolina.

These orders cover aspects such as the discovery process, bellwether case selection, master complaint creation, short form complaints, direct filing in the MDL, and plaintiff fact sheets.

The judge is actively advancing the litigation, with a recent case status conference held on November 16, during which the progress and future plans were discussed.

The parties involved have proposed a bellwether trial plan, which involves selecting a small number of cases to be tried first.

These trials, presided over by the MDL judge, serve as indicators for trends and potential settlement amounts for the remaining cases in the larger group.

The plan includes the exchange of lists of 24 cases each by July 1, 2024, leading to the selection of 15 cases for Discovery Group 1 by December 17, 2024.

This process may seem slow to those unfamiliar with mass tort litigation but is considered relatively fast in cases like this class action lawsuit.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

In preparation for a case management conference, attorneys involved in federal lawsuits against Becton, Dickinson & Co. and its Bard subsidiaries presented different proposals for selecting a limited number of cases for early trial dates.

These trials aim to assess the validity of claims alleging defects in Bard PowerPort catheters, which are prone to fracture, fail, or cause infections.

Numerous product liability lawsuits have been filed against the companies, with plaintiffs asserting complications and injuries resulting from the design of the Bard PowerPort device.

Plaintiffs argue that design problems with the catheters have caused a range of injuries due to material degradation, bacterial growth, and fragmenting.

To streamline the litigation, the U.S. Judicial Panel on Multidistrict Litigation centralized the cases before U.S. District Judge David G. Campbell in Arizona into the Bard PowerPort MDL.

During a recent case status conference, attorneys submitted a joint memorandum outlining issues, including a proposal for a bellwether trial plan.

The plan suggests the exchange of 24 representative cases from each party, totaling 48, by July 1, 2024, forming the initial plaintiff pool.

After initial discovery, 15 cases will be selected for Discovery Group 1 by December 17, 2024, with each party choosing five cases and jointly selecting the last five.

However, there is disagreement between plaintiffs and defendants regarding the number of bellwether trials and whether they can involve multiple plaintiffs simultaneously.

Plaintiffs advocate for 10 bellwether trials to gauge jury reactions and consider consolidated trials involving multiple plaintiffs to gather more data for settlement negotiations.

Defendants contend that seven bellwether trials are sufficient and oppose consolidated trials with multiple plaintiffs.

Notably, defendants will not seek case dismissals based on federal preemption and acknowledge the sufficiency of plaintiffs’ claims.

The selection process for the 15 discovery pool cases will be addressed in future case management orders.

While the outcomes of these early trials won’t affect other pending claims in the MDL, they will have a significant impact on potential Bard PowerPort settlements and their negotiation strategies.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

Bard PowerPort MDL Judge Campbell has instructed the parties to collaborate in submitting proposed protective orders, electronic discovery orders, and preservation orders by October 27, 2023.

Additionally, he has mandated that the parties engage in discussions about various initial matters, including the structure of complaints and direct filing orders.

The next hearing is scheduled for November 16, 2023, in Phoenix.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

There have been a total of 50 cases consolidated in the Bard Implanted Port Catheter Products Liability Litigation (MDL 3081) so far.

The Bard PowerPort Lawsuits were consolidated into an MDL just a few months ago in the same court (US District Court for the District of Arizona) as the Bard IVC Filter litigation.

A group of plaintiffs’ attorneys submitted a document to Judge Campbell regarding requested leadership in the litigation.

The plaintiffs selected Rebecca Phillips, Adam M. Evans, and Michael Sacchet to serve on the co-lead counsel for the litigation.

Dozens of other members were selected for positions like on the Executive Counsel or Steering Committee.

The document also included a request from the plaintiffs to allow this counsel to take control over how the MDL is managed.

Visit this page for more updates on the Bard PowerPort Lawsuit as they become available.

If you or a loved one were injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit claim. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort Lawsuit instantly.

On August 8th, 2023, the United States Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order for the consolidation of Bard PowerPort fracture and migration cases.

These cases will undergo coordinated pretrial proceedings in the U.S. District Court for the District of Arizona, presided over by Judge David G. Campbell.

If you or a loved one used an implanted Bard PowerPort device and were subsequently injured, you may be eligible to file a Bard PowerPort Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for a Bard PowerPort Lawsuit instantly.

The Bard PowerPort Lawsuit is ongoing and our lawyers are speaking to potential clients about their eligibility to file a claim. 

In late May, a motion was submitted to the JPML seeking the consolidation of Bard Power Port cases into a multidistrict litigation (MDL).

According to the motion, the identified defect and injury associated with these cases involve the shedding of barium sulfate particles from the catheter surface, resulting in microfractures, fissures, and other changes to the polymeric structure.

These conditions contribute to several common injuries related to these devices:

• Catheter fracture
• Catheter infection
• Thromboembolism

A recent request has been made to the Judicial Panel on Multidistrict Litigation, urging them to consolidate all ongoing lawsuits related to Bard PowerPort product liability in federal courts.

The motion states that currently there are 10 PowerPort lawsuits pending in different federal districts, but it anticipates a significant increase in the number of cases in the coming year.

Despite the growing number of federal lawsuits against Bard Access Systems and other parties, all of which involve similar allegations of serious complications resulting from the design of the port catheter, the manufacturer is resisting the consolidation of these lawsuits under a single judge for pretrial proceedings.

The plaintiffs argue that the Bard Ports are inherently flawed in their design, leading to fractures, infections, blood clots, and other complications.

If you or a loved one used an implanted Bard PowerPort device and were subsequently injured, you may eligible to file a Bard PowerPort Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for a Bard PowerPort Lawsuit instantly.